PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to announce its 2008 fourth quarter and year-end results on Wednesday, February 25, 2009 by press release after the financial markets close.
Following the release, Medarex's management will host a conference call and live webcast at 4:30 p.m. Eastern Time. To access the call live, please dial 1-866-804-6925 (U.S./Canada) or 1-857-350-1671 (international) and enter passcode number 405-36-543. The webcast can be accessed through the Investor Relations section of Medarex's website at www.medarex.com and will be archived for 7 days following the webcast.
A telephonic replay of the conference call will be available until midnight Eastern Time, March 5, 2008. Access numbers for this replay are 1-888-286-8010 (U.S./Canada) or 1-617-801-6888 (international); passcode number 263-79-360.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com .
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
|SOURCE Medarex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved